All News

cancer, melanoma, metastatic, cell

Increased Cancer Risk with Autoimmune Disorders

Jack Cush, MD

The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.

Read Article
cost.healthcare.jpg

The Effect of Socioeconomic Status on Lupus Outcomes

Jack Cush, MD

Socioeconomic status (SES) often associates with poorer outcomes in systemic lupus erythematosus (SLE) patients; and a current study suggests this is unrelated to healthcare access issues.

Read Article
lupus,nephritis,GN

Tacrolimus Measures Up in Lupus Nephritis Trial

MedPage Today

In a phase III trial, oral tacrolimus (Prograf) proved non-inferior to intravenous cyclophosphamide for treating lupus nephritis, researchers said.

Read Article
RheumNow Podcast square

Lupus Worries (3-25-22)

Jack Cush, MD

Dr. Jack Cush Reviews the news and journal reports from the past week in RheumNow.com.

Read Article
hospital,surgery

SLE Higher Risk of Postoperative Cardiac Events

Jack Cush, MD

ACR Open Rheumatology reports that systemic lupus erythematosus (SLE) patients have a higher risk of postoperative major adverse cardiac events (MACE) that can be identified by common cardiac risk measures.

Read Article
malar lupus

Poor Outcomes in Lupus Patients Not at Target

Jack Cush, MD

A prospective, longitudinal systemic lupus erythematosus (SLE) cohort study examined outcomes and showed that failure to control SLE was common and associated with poorer outcomes including organ damage, glucocorticoid exposure, poor quality of life, and increased mortality.

Read Article
Your Lupus Questions from RNL 2022 Rheumatologists questions for Dr. Jack Cush QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/845D5KfUzY https://t.co/RtKopcTfiY

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 119 SLE pts (30 w CKD) shows urinary galectin-3 binding protein as a biomarker, increased w/ active LN, significantly (p<0.001)correlating w/ SLEDAI, SLICC RAS, histologic activity; higher in proliferative vs membranous LN (p=0.04) https://t.co/s8mRnfxIj6 https://t.co/s1OoiRy6Xi

Links:

Dr. John Cush RheumNow ( View Tweet)
Infection in lupus is suggested by very high CRP, PMN-lymph ratio (NLR) Plt-lymph ratio(PLR). Study of 104 hospitalized SLE found all very high w/ infx & Combined cutoffs of CRP >20 mg/L, NLR >3.5, PLR >151 had 87 sensitivity & 81% specificity for infx https://t.co/5SjFsrBiZp https://t.co/0Ipussd9fF

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Montreal General Hosp SLE cohort study of 489 SLE pts - 35% have Raynauds phenomena; RP in SLE assoc. w/ Female (OR 2.43), White (OR 1.85), CNS disease (OR 1.98), RNP Abs (OR 3.0); negatively assoc w/ hemolytic anemia & cellular casts https://t.co/5t3GL4jqrm https://t.co/gVVqccvtca

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast available on Lupus worries. Download wherever you get your podcasts. https://t.co/gU1mmRXYUi https://t.co/54IDshqNYd

Links:

Dr. John Cush RheumNow ( View Tweet)
Poor Outcomes in Lupus Patients Not at Target A prospective, longitudinal SLE cohort study examined outcomes and showed that failure to control SLE was common/associated with poorer outcomes including organ damage, glucocorticoid exposure, and more. https://t.co/wQMmPgbmWF https://t.co/ROeZU56cfy

Links:

Dr. John Cush RheumNow ( View Tweet)
Montreal General Hosp SLE cohort study of 489 SLE pts - 35% have Raynauds phenomena; RP in SLE assoc. w/ Female (OR 2.43), White (OR 1.85), CNS disease (OR 1.98), RNP Abs (OR 3.0); negatively assoc w/ hemolytic anemia & cellular casts https://t.co/dUxAAIIyya https://t.co/ttIt9pDsTh

Links:

Dr. John Cush RheumNow ( View Tweet)
#ClinicalPearl #Lupus nephritis is often now START w 2 immune suppressive & less total dose of #prednisone & May pulse w 500 mg solumedrol x3 instead of 1g. J Merrill #RNL2022 @RheumNow https://t.co/ePKkPHWhYJ

Links:

Janet Pope Janetbirdope ( View Tweet)

Dr. Peter Lipsky on the "Almighty ANA" "There are 45 million people out there with a +ANA. It is not a good screening tool." @RheumNow #RNL2022 https://t.co/Xtu7kUzd6K
Robert B Chao, MD doctorRBC ( View Tweet)
ANA ▶️Short lived plasma cell DNA. ▶️Long lived plasma cell ANA RNP. Peter Lipsky @rhumnow #Rnl2022 https://t.co/U7YkCBEEFJ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#ClinicalPearl Urinary biomarkers for #SLE #nephritis are still mostly too ‘dilute’ for prime time. Albumin/creative spot urine and #microalbuminuria are still v Impt @RheumNow #RNL2022 https://t.co/uEWs0saSX3

Links:

Janet Pope Janetbirdope ( View Tweet)

Lupus heterogeneity: Anti Smith Anti RNP more common in certain ethnicity , more interferon production and aggressive disease!!! Peter Lipsky @rhumnow #Rnl2022 https://t.co/xGhafD4l8k
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
HEp-2 cell and ACR classification criteria: Peter Lipsky @rhumnow #Rnl2022 https://t.co/6o6epkjqB4
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Avoid screening with ANA, PLEASE!! Normal postive ANA Peter Lipsky @rhumnow #Rnl2022 https://t.co/GEKmhQfpfm
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×